Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Britain Courts Anthropic Amid US Defense Department Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SYDNEY, Australia, July 09, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” the “Company”) today announced that its collaboration partner, the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt Germany (“IKF”), has received the regulatory and ethical approvals for the clinical trial investigating IMP321 in new settings, called ”INSIGHT”.
Approval has been received from the Paul-Ehrlich-Institut (“PEI”), the Federal Institute for Vaccines and Biomedicines for the German Federal Ministry of Health, which is the competent regulatory authority in the field of medicinal products that assesses and monitors antibodies for the treatment of cancer and autoimmune diseases for human use. Approval has also been received from the Institute of Clinical Cancer Research ethics committee. The clinical trial will commence in due course.
The investigator sponsored INSIGHT clinical trial will explore different routes of administration of IMP321 in solid tumours.
The lead investigator of the study, Dr Salah-Eddin Al-Batran, commented, “We are thrilled by the prospect of injecting an active immunotherapy directly at the tumour site to see whether the locally induced antigen presenting cell activation leads to a regression of distant tumour masses, a characteristic of anti-tumour CD8 T cell responses. In addition, analysis of local tumour biopsies before and after IMP321 injection will inform us about the immune infiltrates induced by this APC activator.”
Marc Voigt, Chief Executive of Prima, commented, “We are pleased to see the initiation of this new therapeutic application for IMP321. It is the first ever investigation of whether direct injection of IMP321 into a solid tumour can activate the antigen presenting cells located inside the tumour to boost the body’s immune response.”
About INSIGHT
INSIGHT is an explorative, single centre, open-label, Phase I clinical trial to evaluate the feasibility and safety of intra-tumoural, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3Ig fusion protein) for advanced stage solid tumour entities. The Lead Investigator of this up to 40 patient clinical trial is Professor Doctor Salah-Eddin Al-Batran, the Medical Director of the IKF.
About Prima BioMed
Prima BioMed is listed on the Australian Stock Exchange, and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au
For further information please contact: Prima BioMed Ltd: Australia Investor/Media: Mr Matthew Gregorowski, Citadel-MAGNUS +61 (2) 8234 0100; [email protected] U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected]
